Downloads

1. ADCs vs. AOCs: Shared Design Principles & Key Differences In Bioconjugate Engineering 9/8/2026

   Discover how payload size, charge density, and linker dynamics shape clearance, loading ratios, and intracellular delivery in next-generation oligonucleotide bioconjugates.

2. Risk Managing Through The Void Of ATMP Visible Particle Guidance 9/8/2026

   Regulators expect cell therapy manufacturers to prove they control for visible particles, but guidance remains notably quiet on the matter. Companies must get creative or risk clinical holds.

3. Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option 9/7/2026

   De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

4. Accelerating CAR T-Cell Therapy Manufacturing For Autoimmune Disease 9/7/2026

   Proactive alignment and integrated quality systems can shorten cell therapy timelines. Rapid tech transfer and in-house analytics support regulatory rigor and reduce scaling risks.

5. Next-Generation Enzymes For Targeted Gene Insertion 9/7/2026

   Mining novel recombinases and retrotransposases expands gene-targeting options. AI-driven design improves enzyme activity and specificity, enabling precise, efficient gene insertion.

6. Building Trust In AI For Computerized System Validation 9/4/2026

   Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.

7. A Gentler Cell Line Selection Method Using microRNA 9/4/2026

   Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.

8. Building Robust Potency Assays 9/3/2026

   Robust potency assays depend on reliable biological readouts. Learn how quantitative protein expression analysis can provide sensitive, reproducible measurements of cellular responses.

9. How To Overcome Early Development Challenges Before They Impact Your Program 9/3/2026

   Poor manufacturability and immunogenicity can delay development. Learn how early developability assessments support IND readiness.

10. How Sponsors Should Evaluate Manufacturing Resilience 9/3/2026

    Learn how continuity planning, technology transfer capabilities, global network flexibility, and digital visibility contribute to resilient supply chains and help protect programs from disruption.